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Introduction
Herbal medicines have witnessed a 
substantive growth in popularity underscored 
by their efficacy in alleviating a plethora of 
ailments. This increased usage likely reflects 
their availability, acceptability, and limited 
side effects (1). Basic healthcare needs, such as 
drugs, are in short supply in many developing 
countries and a large proportion of the 
population patronise traditional and alternative 
medicine practitioners. Attractive packaging 
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Abstract
Background: Polyherbal standardised extracts used in ethnomedicine of Eastern Nigeria 
for memory improvements were evaluated for anti-cholinesterases and anti-oxidant properties.
Methods: Anti-cholinesterase, anti-oxidant, and total phenolic and flavonoid contents 
were established using standard procedures.
Results: The three polyherbal extracts exhibited significant concentration dependent 
acetylcholinesterase (AChE) inhibitory activity (P = 0.001). The highest AChE inhibition was 
observed with the Neocare Herbal Tea (NHT) with 99.7% (IC50 = 324 µg/mL); whereas the 
Herbalin Complex Tea (HCT) and Phytoblis Herbal Tea (PHT) exhibited 73.8% (IC50 = 0.2 µg/mL) 
and 60.6% (IC50 = 0.7 µg/mL) inhibition, respectively, relative to eserine at 100% inhibition (IC50 
= 0.9 µg/mL) at 200 µg/mL. The order of percentage increase in inhibition of AChE was NHT > 
HCT > PHT; while the order of decrease in potency was HCT > PHT > NHT. 
Radical scavenging activities of HCT, NHT and PHT were 82.13% (IC50 = 0.08 µg/
mL), 77.43% (IC50 = 0.01 µg/mL) and 76.28% (IC50 = 0.3 µg/mL), respectively, at 1 mg/mL 
concentrations. The reducing power revealed a dose-dependent effect, with NHT > PHT > HCT. The 
order of total phenolics content in the extracts were PHT > HCT > NHT, and for total flavonoids 
content: PHT > NHT > HCT.
Conclusion: The three polyherbal standardised products possess significant 
acetylcholinesterase inhibitory activity and secondary metabolites that could collectively 
contribute to their memory-enhancing effects.
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AD (12, 13). Therefore, AD pathogenesis may 
involve potential interactions between Aβ, 
oxidative stress, and neurofibrillary tangles that 
collectively contribute to disease progression 
and complexity (8, 14, 15, 16). Other related 
emerging biochemical and metabolic pathways 
and targeted drug foci are also emerging (17, 18).  
Today, most reports indicate that 
the etiology of AD, and many other 
neurodegenerative disorders, is based on 
multiple causal factors rather than a single 
etiopathological mechanism (19, 20). 
Underpinning the multifactorial nature of AD, a 
polypharmacy-based therapy with multipronged 
targets (21) might overcome some of the major 
limitations of currently available drugs, whose 
innovation has traditionally relied upon the 
one-molecule, one-target paradigm (22). Hence 
the use of drug entities that display multiple 
target specificity may be of improved therapeutic 
benefit than single-target drugs or combination 
therapy (22, 23). Indeed, recent drug trials 
have suggested that AD treatment using a poly-
pharmacy product may better address the 
multiple etiopathology of AD (24). 
Molecules with anti-cholinesterases and 
anti-oxidant capacity could likely provide 
suitable candidate drugs to modify AD pathology. 
However, direct synthetic anti-oxidants usage 
may be excluded due to potential adverse effects 
(25). Plant based medicines used as natural 
products are reported to possess beneficial 
synergistic activities when used as combinations 
(26). Polyherbal drugs have been widely used 
in adjuvant therapy in the management of 
chronic diseases (27, 28). Therefore, it becomes 
imperative to screen polyherbal products to 
ascertain claims of efficacy, safety and verify 
side effect profiles. Medicinal plant components 
are rich sources of secondary metabolites that 
act synergistically at multiple targets to provide 
important therapeutic effects. 
Hence, three polyherbal formulations: 
Neocare Herbal Tea (NHT), Herbalin Complex 
Tea (HCT), and Phytoblis Herbal Tea (PHT) 
that have been suggested to combat memory 
impairment were screened for possible anti-
cholinesterase, and anti-oxidant effects. The 
rationale for selection of these three polyherbal 
products also relies on the documented multiple 
pharmacological activities of the individual 
components of each of these herbal formulations. 
This is the first scientific report on the activities 
of these standardised polyherbal extracts in vitro. 
and unregulated advertisement of herbal 
products, most especially their presentation 
as supplements or herbal teas have given 
herbal products worldwide appeal. Synthetic 
molecules have yet to completely attenuate 
medical conditions including dementias, such 
as Alzheimer disease (AD), and Parkinson 
disease (PD), hence the need for the continuous 
screening of indigenous medicines to discover 
suitable drugs to alleviate disease symptoms. 
The pathophysiology of AD is complex and 
insidious due to multifaceted mechanisms. In 
AD, acetylcholine (ACh) deficiency underlies 
memory and learning impairment, and this has 
led to the ‘cholinergic hypothesis’ of AD. ACh is 
stored in vesicles and released at nerve terminals 
after nerve cell depolarisation. ACh crosses the 
synaptic cleft where it binds to post-synaptic 
ACh receptors. The levels of synaptic ACh are 
regulated by acetylcholinesterase (AChE), 
hence this has led to the development of several 
classes of AChE inhibitors, such as donepezil, 
galantamine, and rivastigmine, as treatments to 
sustain ACh signaling and limit the cholinergic 
deficit in mild to moderate AD (2–8). The use of 
these drugs and memantine, a non-competitive 
N-methyl-D-aspartate receptor antagonist, may 
limit disease severity, but the development of 
new drugs for AD has been limited. 
Another defining postulate of AD 
pathogenesis and progression is the ‘amyloid-
beta hypothesis’ which attributes the probable 
cause of AD to the distorted production, 
aggregation, and deposition of beta-amyloid 
peptide (Aβ) into neuritic plaques (8). In 
addition, the ‘tau hypothesis’ suggests that the 
formation of intracellular neurofibrillary tangles 
that are composed of hyper-phosphorylated 
tau protein is also neurotoxic and contributory 
to AD pathogenesis and/or progression (9, 
10). Consideration of these paradigms has 
highlighted the quest for disease-modifying 
drugs with broad activities, but few have 
preceded beyond phase 3 clinical trials due to a 
lack of efficacy and patient neurotoxicity (11).
AD neurotoxicity may also be exacerbated 
via the generation of reactive oxygen species 
(ROS), as a consequence of both an accelerated 
generation of ROS and a gradual decline in 
cellular anti-oxidant defense mechanisms 
with senility. Hence mitochondria-targeted 
anti-oxidants have proven to be successful in 
counteracting Aβ toxicity in animal models, and 
in improving cognitive function and behavioral 
deficits in patients with mild to moderate 
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chemical make-up and that this is consistent 
from batch to batch. This practice has developed 
out of the drug model in which reproducible 
amounts of different herbs are consistently 
used for every product dispensed. This differs 
from pharmacy practices in which scientists 
identify the components of a plant(s) that have 
definite pharmacological activity in the body and 
formulate the bioactive agent(s). 
The standardised polyherbal extracts 
were obtained from a herbalist during a herbal 
exposition at the Herbfest conference held in 
October in Abuja, Nigeria in 2014. The crude 
powdered extract of NHT and PHT (100 g each) 
was immersed in 500 mL of methanol for 72 h. 
For the HCT, 80 g was immersed in 400 mL of 
methanol. In each case the mixture was shaken 
twice daily before filtration through a double 
layer gauze to obtain a supernatant that was then 
evaporated to dryness at 50 °C in vacuo. The 
dried methanolic extract yielded 4.22%, 5.53% 
and 5.24% of NHT, HCT and PHT, respectively 
(Table 3.1). The extracts were stored at 4 °C 
until required. Each extract was reconstituted 
with double distilled water before it was used 
in experimental assays. The phytocomposition 
per pack of each polyherbal formula is shown in 
Table 1.
Materials and Methods
Chemicals and Reagents
Acetylthiocholine iodide (ATCI), 
L-ascorbic acid, bovine serum albumin (BSA), 
dimethyl sulphoxide (DMSO), 2,2-diphenyl-
1-picrylhydrazyl (DPPH), 5,5,-dithiobis[2-
nitrobenzoic acid] (DTNB), eserine, ferric 
chloride, Folin-Ciocalteau reagent, gallic acid, 
potassium ferricyanide, β-tocopherol, and 
trichloroacetic acid were all purchased from 
Sigma, UK. All other chemical and reagents 
used in this study were of analytical grade and 
were obtained from Sigma, UK unless stated 
otherwise.
Plants Herbal Samples and Extraction
A standardised herbal extract is an herb 
extract that has one or more components 
present in a specific guaranteed amount usually 
expressed as a percentage. The polyherbal 
standardised extracts used in this investigation 
were herbal extracts having two or more different 
plant materials in a specific guaranteed amount, 
expressed as percentages. The purpose behind 
the polyherbal standardisation is to assure to 
the consumer that the product retains the same 
Table 1. Name of standardised herbal products, components and yield of methanolic extract
S/No. Name of Herbal Product
Constituents/ Common 
name Family Composition Yield (%)
1. Neocare herbal tea 
(NHT)
Alchornea cordifolia
(Christmas bush)
  Euphorbiaceae 25% 4.22
Azadirachta indica
(Neem leaves)
Meliaceae 25%
Pteridium aquilinum
(Eagle Fern)
Dennstaedtiaceae 50%
2. Herbalin complex 
(HCT)
Hippocratea volubilis 
(Hepocretea pollens)
Hippocrataeceae 50% 5.52
Viscum album 
 (mistletoe)
Santalaceae 25%
Thymus pulegiodes
(Mother thyme)
Lamiaceae 25%
3. Phytoblis Herbal Tea 
(PHT)
Urtica dioica 
(Stinging nettles)
Urticaceae 25% 5.24
Hippocretea volubilis
(Hepocretea pollens)
Hippocretaeceae 50%
Thymus vulgaris
(Thyme)
Lamiaceae 25%
Aloe vera Asphodelaceae 25%
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37 °C for 40 min in the dark, before reading 
the absorbance at 517 nm using a Spectramax 
microplate reader. Experimental blanks 
were performed in the absence of polyherbal 
extracts. The percentage anti-oxidant activity 
was estimated as the percent DPPH radical 
scavenging activity. All tests were performed in 
triplicate and inhibition percentages reported as 
means (± SD). 
Assessment of Reducing Power Capacity 
The reducing capacity of polyherbal 
methanolic extracts was evaluated via their 
ability to reduce ferric iron (Fe3+) to ferrous iron 
(Fe2+). Concentrations of polyherbal extracts 
were prepared across a concentration range of 
6.25 µg/mL–50 µg/mL. Aliquots of 4 µL of 5 
mg/mL of each plant sample were added to 400 
µL of phosphate buffer pH 7.4 and 250 µL of 1% 
potassium ferricyanide and incubated at 50 °C 
for 20 min. Then 250 µL of 10% trichloroacetic 
acid was added, and after vortexing, the sample 
was centrifuged at 3000 rpm for 10 min. One 
hundred microlitres of the supernatant was 
removed and mixed with a similar volume of 
water and added to a microtiter plate. Twenty 
microlitres of freshly prepared ferric chloride 
solution was added, resulting in the formation 
of Perls’ Prussian blue, with absorbance read at 
700 nm using a Spectramax plate reader (30, 
33). A blank was prepared without addition of 
anti-oxidant. All assay points were conducted in 
triplicates. L-ascorbic acid was used as a positive 
control anti-oxidant compound. The percentage 
increase of reduction activity with increasing 
concentration of the extracts was assessed. 
Determination of Total Phenolic and 
Total Flavonoid Content 
Quantitation of total phenolics in 
polyherbal extracts utilised the Folin-Ciocalteau 
reagent (FCR) method as detailed in previous 
publications (30, 33). Twenty microlitres of 
polyherbal extracts with concentration range 
of 1 µg/mL–100 µg/mL, was mixed with 90 µL 
of double distilled water, quickly followed by 
the addition of 30 µL of FCR and the mixture 
shaken vigorously on a plate reader. Within 10 
min, 60 µL of 10% Na2CO3 solution was added 
and the material incubated at 40 °C in a shaking 
incubator. After 40 min the absorbance of the 
mixture was read in a Spectramax plate reader 
at 760 nm. Gallic acid (Sigma, CAS14991-7) was 
similarly processed over a concentration range 
of 0.1 mg/mL–0.5 mg/mL as a positive control, 
Determination of Acetylcholinesterase 
Inhibitory Activity Using a Microtiter 
Plate Assay
Acetylcholinesterase (AChE) activity was 
measured in a 96-well microtiter plate assay 
based on the method of Ellman et al. (29), 
as published previously (30). For each assay 
data point, 50 µL of 3 mM 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB), 50 µL of AChE 
(1 mg/mL) (Sigma, C3389) or rat brain 
homogenate (prepared according to previous 
publications (31, 32)), 35 µL of 50 mM Tris/
HCl pH 8.0, and 40 µL of polyherbal extract 
were mixed and incubated at 37 °C. The assay 
was initiated by addition of 25 µL of 15 mM 
acetylthiocholineiodide (ATCI), with production 
of 5-thio-2-nitrobenzoate anion read at 412 
nm every 30 sec for 10 min using a Spectramax 
microplate reader (ThermoFisher, UK). Assay 
reactions with polyherbal extracts were all 
performed in triplicate at concentrations of 200 
µg/mL, 20 µg/mL, 2 µg/mL, 0.2 µg/mL and 0.02 
µg/mL. A negative control assay performed in 
the absence of AChE provided a reagent blank. 
Eserine (Sigma, E8375) was used as a positive 
control to inhibit electric eel or rat brain AChE 
in a dose-dependent manner. The percentage 
inhibition of AChE by polyherbal extract was 
calculated relative to inhibition by eserine, with 
the herbal extract concentration producing 
50% inhibition (IC50) of AChE calculated using 
GraphPad Prism (version 5.03, Inc., 2010, San 
Diego California USA) via non-linear regression 
analysis.
Assessment of 2,2-Diphenyl-1-
Picrylhydrazyl Radical Scavenging 
Activity
A 2,2-diphenyl-1-picrylhydrazyl (DPPH) 
assay was employed, to determine by a 
spectroscopic method, the anti-oxidant capability 
via free radical scavenging activity of polyherbal 
extracts using a method described previously 
(33). Stock solutions of each of the polyherbals 
(5 mg/mL) were diluted to final concentrations 
of 200 µg/mL, 100 µg/mL, 50 µg/mL, 25 µg/
mL, 12.5 µg/mL, and 6.25 µg/mL in ethanol. 
One hundred and sixty microlitres of 0.1 mM 
DPPH in ethanol was added to 20 µL of extract 
or fraction, or Vitamin E (as a positive control), 
and the material was mixed with 20 µL of water. 
β-tocopherol was used as control and assayed 
over a concentration range of 1.56 mg/mL, 
0.78 mg/mL, 0.39 mg/mL, 0.195 mg/mL and 
0.0975 mg/mL. The mixture was incubated at 
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Smirnov (K-S) test which was conducted in 
SPSS. The concentration of agent producing 50% 
inhibition (IC50) was calculated using non-linear 
regression analysis with the GraphPad Prism 
(Version 5.03) for Windows (GraphPad Software, 
Inc., San Diego, CA, USA, www.graphpad.com).
Results
Composition of Standardised Herbal 
Products and Yield of Methanolic 
Extracts
Polyherbal standardised products: 
Neocare herbal tea (NHT), Herbalin complex 
tea (HCT) and Phytoblis herbal tea (PHT) used 
for memory improvement in ethnomedicine 
of Eastern Nigeria have three or four herbs. 
Neocare herbal tea (NHT) contains standardised 
plants materials such as Alchornea cordifolia 
(Euphurbiaceae) leaves, Azadirachta indica 
(Meliaceae) and Pteridium aquilinum 
(Dennstaedtiaceae); HCT contains Hippocratea 
volubilis (Hippocrateaceae), Viscum album 
(Santalaceae) and Thymus pulegiodes 
(Lamiaceae); PHT contain Urtica dioica 
(Urticaceae) stinging nettles, Hippocratea 
volubilis (Hippocrateaceae), Thymus vulgaris 
(Lamiaceae), and Aloe vera (Asphodelaceae). 
The composition and yield of each extract of 
these polyherbal products is presented in Table 1.
Polyherbal Extracts Exhibited 
Acetylcholinesterase Inhibitory Activity 
The three polyherbal methanolic extracts 
exhibited significant (P = 0.001) concentration 
dependent AChE inhibitory activity (Figure 1). 
The polyherbal NHT extract had the highest 
AChE inhibition of 99.7% (IC50 = 324 µg/
mL); HCT demonstrated 73.8% (IC50 = 0.2 µg/
mL) and PHT gave 60.6% (IC50 = 0.7 µg/mL) 
inhibition while the pure drug, eserine, 100% 
inhibition (IC50 = 0.6 µg/mL) at 200 µg/mL. 
The order of percentage increase in inhibition of 
AChE was NHT > HCT > PHT; while the order 
of potency decreased according to HCT > PHT > 
NHT. The IC50 values are included in Table 2.
Polyherbal Extracts Exhibited DPPH 
Radical Scavenging Activity 
The polyherbal methanolic extracts 
exhibited DPPH radical scavenging activity in a 
concentration-dependent manner (Figure 2). The 
percentage DPPH radical scavenging by each of 
the polyherbal extracts were HCT: 82.13% (IC50 = 
and was used to generate a calibration curve 
for quantification of total phenolic content in 
polyherbal extracts across the concentration 
range of 0.01 mg/mL–0.05 mg/mL. Total 
phenolic content was expressed as mg gallic acid 
equivalents/gram of plant extract (mg GAE/g).  
Total flavonoid content of polyherbal 
extracts was determined similar to the method 
described by Zhishen et al. (34), as previously 
published (30), using quercetin as a reference 
compound. Twenty microlitres of polyherbal 
extract (5 mg/mL) in ethanol was mixed in a 
microplate well with 200 μL of 10% aluminum 
chloride solution and 1M potassium acetate 
solution. The mixture was incubated for 30 
min at room temperature before measuring the 
absorbance at 415 nm using a Spectramax plate 
reader. The total flavonoids content of polyherbal 
extracts was quantified as mg quercetin 
equivalent per gram of polyherbal extract (mg 
QUER equivalent/g).
Cytotoxicity Assays
Cell culture
Hepatocellular carcinoma (HepG2) cells 
were cultured in Eagle’s minimal essential 
media (EMEM) with 2 mM Glutamine, 1% Non-
Essential Amino Acids (NEAA), 10% Foetal 
Bovine Serum (FBS), and antibiotics (100 μg/mL 
penicillin and 100 μg/mL streptomycin). Cells 
were grown in a humidified atmosphere at 37 °C 
and 5% CO2.
Cytotoxicity assays
Cells were seeded at 3 × 104 cells per well 
in 96-well plates. At ~80%–90% confluence, 
polyherbal standardised extracts were added 
to wells at 1 μg/mL, 10 μg/mL, 100 μg/mL, and 
1000 μg/mL. After 48 h, treatment media was 
removed, and cells incubated with fresh media 
containing 0.5% thiazolyl blue tetrazolium 
bromide (MTT) reagent (Sigma, M2128). After 4 
h at 37 °C in the humidified incubator, the media 
was replaced with 100 μL of isopropanol and 
DMSO solution (1:1 (v/v)) and the absorbance 
read at 540 nm in a Spectramax plate reader. 
Each assay point was conducted in triplicate. 
The percentage of cells that were metabolically 
active was calculated for each concentration of 
polyherbal methanolic extract.
Statistical Analysis
Results are expressed as means (± SD). 
Normality was assessed by the Kolmogorov-
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contents (TFC) are shown in Figure 4B. TFC 
values were estimated using the standard curve 
for quercetin (y = 0.0244x + 0.161; R2 = 0.974). 
The results showed that the TFC content was 
in the order PHT > NHT > HCT and was dose 
dependent (P < 0.0001). 
Polyherbal Extracts are Tolerated by 
Liver Cells at High Doses
Polyherbal standardised extracts were 
evaluated for cytotoxicity to human liver 
HepG2 cells. Cytotoxicity was observed to be 
concentration-dependent but with significant 
loss of metabolic activity only at the highest 
dose employed for all extracts (1000 µg/mL). 
HepG2 cell metabolic activity at 1000 µg/mL was 
~43%, 66%, and 71% for NHT, HCT and PHT, 
respectively. Cytotoxicity effects of the polyherbal 
extracts were minimal at lower doses. The 
IC50 viability values for the polyherbal extract 
were in the order: PHT > HCT > NHT. The 
cytotoxicity profile of these three standardised 
herbal extracts was negligible and approximately 
equipotent at 10 µg/mL. Some extracts, however, 
moderately increased the metabolic activity of 
the cells at certain concentrations (Table 3).
0.08 µg/mL), NHT: 77.43% (IC50 = 0.01 µg/mL) 
and PHT: 76.28% (IC50 = 0.3 µg/mL) inhibition, 
respectively, at 1 mg/mL concentration. IC50 
values have been included in Table 2.
Polyherbal Methanolic Extracts 
Displayed Reducing (Anti-Oxidant) 
Activity
The polyherbal methanolic extracts 
demonstrated a concentration-dependent 
increase of anti-oxidant (reducing) capacity 
with increasing extract concentration (Figure 
3). Reducing power of the different herbal 
extracts was not as effective as the standard 
drug, ascorbic acid. The reducing power of the 
polyherbal extracts was in the order: NHT > PHT 
> HCT at 50 μg/mL. 
Total Phenolic Content and Total 
Flavonoid Content of Polyherbal Extracts
The total phenolic content (TPC) of the 
polyherbal extracts are shown in Figure 4A. 
The TPC of the extracts were calculated using 
the standard curve for Gallic acid (y = 0.006x 
+ 0.147; R2 = 0.996). The order of TPC in the 
polyherbal extracts revealed that PHT > HCT 
> NHT. The results of aluminum chloride 
colorimetric determination of total flavonoid 
Figure 1. Acetylcholinesterase inhibitory activity of polyherbal extracts. Values presented as mean 
percentage inhibition ± SD, n = 3
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Table 2. AChE inhibitory and DPPH radical scavenging activities of polyherbal extracts
S/No. Polyherbal MethanolicExtracts / pure drugs
Inhibitory concentration (IC50)
Anticholinesterases activity Antioxidant activity
1. NHT 324.0 ± 3.9 0.01 ± 0.023
2. HCT 0.20 ± 0.7 0.08 ± 0.0032
3. PHT 0.70 ± 2.9 0.30 ± 0.0020
4. Eserine 0.90 ± 0.03 -
5. α-Tocopherol (vitamin E) - 20.0 ± 0.002
All values are reported as means ± SD (n = 3). Polyherbal extract inhibition of AChE was measured using a modified Ellman assay, 
with percentage inhibition of AChE calculated relative to eserine; polyherbal anti-oxidant activity was assessed via the percentage 
inhibition (radical scavenging) of DPPH with vitamin E used as a positive control.  
Figure 2. Antioxidant activity of polyherbal extracts. Values presented as mean percentage inhibition 
± SD, n = 3
Table 3. Effect of standardised polyherbal methanolic extracts on HepG2 cells viability
S/No. Polyherbal Extracts 1 µg/mL 10 µg/mL 100 µg/mL 1000 µg/ mL IC50 (µg/mL)
1. NHT 111.3±3.5a 107.5±9.2 70.1±6.3b 43.2±5.22c ~745
2. HCT 105±5 103.5±7.25 91.6±6.4 65.65±9.34c ~1400
3. PHT 104.7±7.5 102.4±3.4 95.4±6.36a 71.2±5.3c >1650
HepG2 cells were incubated with polyherbal extracts at the specified concentration for 48 h and the percentage of viable cells 
evaluated using a MTT assay. Polyherbal extracts were assessed at least in triplicate across a 1 µg/mL–1000 µg/mL concentration 
range, and an approximate IC50 calculated.
All values are reported as means (±SD) (n = 3)   aP = 0.043, bP = 0.006, cP = 0.0001.
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Figure 3. Reducing capacity of polyherbal extracts. Values presented as mean percentage inhibition 
± SD, n = 3
Figure 4. Total phenolic content (A), and total flavonoid content (B) of polyherbal extracts. Values 
presented as mean ± SD, n = 3
Original Article | Memory enhancing effect of standardised herbal extracts
www.mjms.usm.my 35
unknown, and may also contribute to the anti-
AChE activity we detected for the polyherbal 
product, but we have yet to investigate this 
further. 
The phytoconstituents of HCT includes 
Hippocratea volubilis (Hippocreateaceae), 
Viscum album (Santalaceae), and Thymus 
pulegiodes (Lamiacene) in the ration of 2:1:1. 
A new triterpene caffeoyl ester, lupeol caffeate 
was obtained from Hippocratea volubilis 
(39) with reported benefits to a broad range 
of diseases (40). Viscum album is reported to 
exhibit sedative, anti-epileptic and anti-psychotic 
activity in mice (41), anti-oxidant capacity (4), 
as well as anti-amyloid β and anti-dementia 
effects, and therefore may have a therapeutic role 
in the prevention of the progression of AD (42). 
Thymus pulegiodes is a rich source of natural 
anti-oxidants and AChE inhibitors, which may be 
useful in preventing and treating AD and other 
neurodegenerative disorders (43).
PHT contains Urtica dioica, Hippocratea 
volubilis, and Thymus vulgaris in the ratio of 
1:2:1. Luteolin, a flavonoid has been isolated 
from Thymus vulgaris and is known to possess 
anti-amyloid activity (44, 45). Urtica dioica has 
been reported to possess anti-oxidant and anti-
microbial activities (46).
An assessment of the anti-oxidant activity 
via DPPH free radical scavenging and ferric 
iron reducing capacity demonstrated that NHT 
was the most active polyherbal agent. Anti-
inflammatory (47, 48, 49) and anti-oxidant 
(50) effects of agents from NHT (Alchornea 
cordifolia) have also been reported. Likewise 
Alchornea cordifolia alone also has a relatively 
high total phenolic content with useful free 
radical scavenging activity reported (51). 
Conclusion
The phytocomponents of these polyherbal 
products possess significant anti-cholinesterase, 
and anti-oxidant activities (refer to graphical 
abstract). These inherent pharmacological 
properties are useful to address multiple 
elements of the etiopathology of AD, and 
therefore lay credence to the potential use 
of ethnomedicine by herbalists for memory 
enhancing activity. These polyherbal extracts 
remain a potentially beneficial pharmacotherapy 
for the management of diseases with cholinergic 
deficits, such as AD, PD, and myasthenia gravis. 
Discussion
Neurodegenerative diseases may be 
exacerbated by the generation of free radicals 
and associated cellular redox stress, a process 
that could be effectively and efficiently 
ameliorated by herbal products that possess 
anti-oxidant activity. Ethnomedicine has 
utilised polyherbal formulations purported 
to have multiple health benefits (28). Indeed, 
standardised extracts may have wide acceptance 
since they can produce reproducible therapeutic 
effects comparable to crude extracts (28). 
Clinical effectiveness requires delivery of an 
active dosage and the use of standardised 
extracts is an innovative way to assure the 
delivery of an effective dosage (35). 
Several reports have evaluated the 
phytocomponents of PHT, HCT and NHT, 
however, prior to this study no data exists on 
the anti-cholinesterase activity or anti-oxidant 
effects of these polyherbal combinations. 
The effect of polyherbal extracts on one of 
the primary defects in AD; that of a deficit in 
acetylcholine signaling, was indirectly assessed 
via their ability to inhibit AChE. The screening 
investigation confirmed that all three polyherbal 
products exhibited significant, and dose-
dependent inhibition of AChE. AChE inhibitory 
activity was highest (99.7%) with the NHT 
extract, however this also had the lowest potency 
(IC50 = 324 µg/mL). The other two extracts HCT 
and PHT displayed AChE inhibition of 61%–
74%, and both with considerable potency (IC50 
between 0.2 µg/mL–0.7 µg/mL), comparable 
and indeed slightly lower than the pure drug 
eserine at 0.9 µg/mL. 
The NHT formulation contains Alchornea 
cordifolia (Euphorbiaceae), Azadirachta 
indica (Meliaceae) and Pteridium acquilinum 
(Dennstaedtiaceae) in the ratio of 1:1:2 with a 
4.22% yield upon 50% methanolic extraction. 
Of these three plants, it is only the aqueous bark 
extracts of Azadiracta indica that have been 
reported previously to have AChE inhibitory 
activity (36). Furthermore, Azadiracta 
indica has been reported to be effective in 
an experimental model of AD by virtue of its 
cognition enhancement, anti-depressant and 
anti-anxiety properties (37). Although not 
reported for Alchornea cordifolia, another 
member of the Eurphorbiaceae family, Jatropha 
gossypifolia L has been reported to exhibit AChE 
inhibitory activity (38). The role of Pteridium 
acquilinum on memory enhancement is as yet 
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